BIOMAT Database Logo BIOMAT Database Logo

Evaluation of two dose schedules of 15 (S) 15 methyl PGF2alpha methyl ester vaginal suppositories for dilatation of cervix prior to vacuum aspiration for late first trimester abortions. 1977

B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011460 Prostaglandins F (9 alpha,11 alpha,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid (PGF(1 alpha)); (5Z,9 alpha,11,alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid (PGF(2 alpha)); (5Z,9 alpha,11 alpha,13E,15S,17Z)-9,11,15-trihydroxyprosta-5,13,17-trien-1-oic acid (PGF(3 alpha)). A family of prostaglandins that includes three of the six naturally occurring prostaglandins. All naturally occurring PGF have an alpha configuration at the 9-carbon position. They stimulate uterine and bronchial smooth muscle and are often used as oxytocics. PGF
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000032 Abortion, Therapeutic Abortion induced to save the life or health of a pregnant woman. (From Dorland, 28th ed) Therapeutic Abortion,Abortions, Therapeutic,Therapeutic Abortions
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013488 Suppositories Medicated dosage forms that are designed to be inserted into the rectal, vaginal, or urethral orifice of the body for absorption. Generally, the active ingredients are packaged in dosage forms containing fatty bases such as cocoa butter, hydrogenated oil, or glycerogelatin that are solid at room temperature but melt or dissolve at body temperature. Rectal Suppositories,Vaginal Suppositories,Vaginal Suppository,Suppositories, Rectal,Suppositories, Vaginal,Suppository, Vaginal

Related Publications

B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Dilatation of the cervix prior to vacuum aspiration by single vaginal administration of 15-methyl-PGF2 alpha methyl ester.
June 1980, Contraception,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Successful first trimester abortion with 15(S) 15-methyl-prostaglandin F2alpha-methyl ester vaginal suppositories.
January 1976, Contraception,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Evaluation of 15(S) 15-methyl-PGF 2 alpha-methyl ester vaginal suppositories for cervical dilatation and second trimester pregnancy termination.
December 1976, Contraception,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Evaluation of vaginal delivery systems containing 15[s]15-methyl PGF2alpha methyl ester.
January 1976, Prostaglandins,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Preoperative dilatation of the cervix by single vaginal administration of 15-methyl-PGF2alpha-methyl ester.
October 1977, Prostaglandins,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Preoperative cervical dilatation with 15(S)15-methyl PGF2alpha methyl ester pessaries.
January 1978, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Induction of abortion with 15(S)-15-methyl PGF2alpha (Tham) vaginal suppositories.
January 1977, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Three methods for gradual cervical dilatation prior to vacuum aspiration in late first trimester pregnancy.
September 1983, Contraception,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Induction of first and second trimester abortion by the vaginal administration of 15-methyl-PGF2alpha methyl ester.
January 1976, Advances in prostaglandin and thromboxane research,
B Zoremthangi, and N Agarwal, and C P Puri, and K R Laumas, and L K Saraya, and V Hingorani
Vaginal administration of 15-methyl-PGF2 alpha-methyl ester prior to vacuum aspiration. Peri- and postoperative complications.
January 1983, Acta obstetricia et gynecologica Scandinavica,
Copied contents to your clipboard!